ArticleJournal of robotic surgery2026
Perioperative glucagon-like peptide-1 receptor agonist use and surgical outcomes in patients with morbid obesity (BMI > 35) undergoing robotic urologic surgery: A propensity score-matched analysis.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the association between established glucagon-like peptide-1 receptor agonist (GLP-1RA) use and postoperative outcomes in obese patients undergoing robotic urologic surgery. Single-center retrospective cohort study of 361 adults with BMI ≥ 35 undergoing robotic-assisted radical prostatectomy, partial nephrectomy, or radical nephrectomy from 2017 to 2024. Established GLP-1RA exposure required ≥ 3 months of documented use before and after surgery. Propensity score was used for 2:1 nearest-neighbor matching (36 GLP-1RA users, 59 controls). The primary outcome was any complication (Clavien-Dindo classification); secondary outcomes included major complications (Clavien-Dindo ≥ III), comprehensive complication index (CCI), estimated blood loss (EBL), length of stay (LOS), peak pain score, and emergency department (ED) utilization at 90 days and 1 year. Covariate balance was achieved (mean absolute SMD 0.036; maximum 0.074). GLP-1RA use was not associated with any complication (OR 2.39, 95% CI 0.63-9.10), major complications (OR 3.70, 95% CI 0.45-30.32), or CCI (mean difference 1.29, p = 0.64). EBL was reduced but nonsignificant (mean difference - 81.32 mL, 95% CI -165.85 to 3.22, p = 0.06); LOS was shorter but nonsignificant (mean difference - 0.78 days, p = 0.11). Peak pain scores and ED utilization did not differ. Established GLP-1RA use was not associated with increased postoperative complications, morbidity, or ED utilization in obese patients undergoing robotic urologic surgery. While power constraints preclude conclusions of equivalence, these findings provide the first urologic-specific perioperative safety data and support individualized rather than reflexive GLP-1RA discontinuation in this growing surgical population.
Indexed as
Identifiers
42213238What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.